Gold bars to be exempt from tariffs, White House clarifies
Bliss Kelly, President of U.S. Group Health at Teladoc Health, Inc. (NYSE:TDOC), sold a portion of her company shares, according to a recent SEC filing. The transaction comes as the telehealth provider, currently valued at $1.47 billion, has seen its stock decline by approximately 47% over the past year. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value assessment. On March 20, Kelly sold 9,470 shares of common stock at a price of $8.424 per share, totaling approximately $79,775. This transaction reduced her total holdings to 45,384 shares.
In an earlier transaction on March 19, Kelly acquired 19,433 shares of common stock through the conversion of restricted stock units, which were granted as part of her compensation. These units were converted on a one-for-one basis with no cash exchanged, increasing her stock ownership to 54,854 shares before the subsequent sale.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $640.5 million, which slightly surpassed the forecast of $638.5 million. However, the company reported an earnings per share (EPS) of -0.28, falling short of the expected -0.23. The full-year revenue for 2024 was $2.6 billion, marking a 1% decrease from the previous year. Meanwhile, Teladoc announced a new partnership with Gifthealth, a pharmacy partner for Eli Lilly (NYSE:LLY)’s LillyDirect program, to enhance its Comprehensive Weight Care Program by facilitating access to the medication Zepbound® (tirzepatide).
Analysts from Stifel and Needham maintained a Hold rating on Teladoc’s shares, citing mixed fourth-quarter results and a cautious outlook for 2025. Truist Securities also reiterated a Hold rating with a price target of $10, emphasizing the potential benefits of the new partnership for Teladoc’s weight care program. The collaboration with Gifthealth is part of Teladoc’s efforts to expand access to evidence-based care and improve medication availability for members without insurance coverage for obesity treatments.
Teladoc’s guidance for 2025 indicates flat to slight revenue growth, with adjusted EBITDA expected to range between $278 million and $319 million. The company is focusing on stabilizing its BetterHelp segment and expanding its international business. Despite the challenges, Teladoc added 4 million U.S. members in 2024 and completed nearly 1 billion mental health visits, highlighting continued demand for its virtual care services.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.